Interferon-γ and granulocyte-macrophage colony stimulating factor therapy in three patients with pulmonary aspergillosis

Infection

Volumn 36, Issue 4, 2008, Pages 368-373

  Bandera, A ^a   Trabattoni, D ^b   Ferrario, G ^c   Cesari, M ^c   Franzetti, F ^c   Clerici, M ^b   Gori, A ^a,c  

^a SAN GERARDO HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ITRACONAZOLE; MIELOGEN; RECOMBINANT GAMMA INTERFERON; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASPERGILLUS; CASE REPORT; CELL PROLIFERATION; CYTOKINE PRODUCTION; DRUG WITHDRAWAL; EMPYEMA; FEMALE; FEVER; HUMAN; LEUKOCYTE; LUNG ASPERGILLOSIS; LUNG INFILTRATE; LUNG LESION; MALAISE; MALE; PLEURA EFFUSION; PNEUMOTHORAX; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ASPERGILLOSIS; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HIV INFECTIONS; HUMANS; INTERFERON TYPE II; LUNG DISEASES, FUNGAL; MALE;

EID: 50649096799     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-008-7378-7     Document Type: Article

References (17)

1. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340: 764-771.
2. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
3. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563-1571.
4. Roilides E, Sein T, Roden M, Schaufele RL, Walsh TJ: Elevated serum concentrations of interleukin-10 in nonneutropenic patients with invasive aspergillosis. J Infect Dis 2001; 183: 518-520.
5. Hebart H, Bollinger C, Fisch P, et al. Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies. Blood 2002; 100: 4521-4528.
6. Shao C, Qu J, He L, et al. Transient overexpression of γ interferon promotes Aspergillus clearance in invasive pulmonary aspergillosis. Clin Exp Immunol 2005; 142: 233-241.
7. Gil-Lamaignere C, Simitsopoulou M, Roilides E, Maloukou A, Winn RM, Walsh TJ: Interferon-γ and granulocyte-macrophage colony-stimulating factor augment the activity of polimorphonuclear leukocytes against medically important zygomycetes. JID 2005; 191: 1180-1187.
8. Safdar A, Rodriguez GH, Lichtiger B, et al. Recombinant interferon γ1b immune enhancement in 20 patients with haematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer 2006; 106: 2664-2671.
9. Safdar A, Rodriguez G, Ohmagari N, Kontoyiannis DP, Rolston KV, Raad II, Champlin RE: The safety of interferon-γ-1b therapy for invasive fungal infections after haematopoietic stem cell transplantation. Cancer 2005; 103: 731-739.
10. Boots RJ, Paterson DL, Allworth AM, Faoagali JL: Successful treatment of post-influenza pseudomembranous necrotising bronchial aspergillosis with liposomal amphotericin, inhaled amphotericin, inhaled amphotericin B, gamma interferon and GM-CSF. Thorax 1999; 54: 1047-1049.
11. Saulsbury FT: Successful treatment of Aspergillus brain abscess with itraconazole and interferon-gamma in a patient with chronic granulomatous disease. Clin Infect Dis 2001; 32: E137-E139.
12. Ozsahin H, von Planta M, Muller I, et al. Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin B. Blood 1998; 92: 2719-2724.
13. Kelleher P, Goodsall A, Mulgirigama A, et al. Interferon-γ therapy in two patients with progressive chronic pulmonary aspergillosis. Eur Respir J 2006; 27: 1307-1310.
14. Asciouglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and haematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
15. Boyd A, Modi S, Howard SJ, Moore CB, Keevil BG, Denning DW: Adverse reactions to voriconazole. Clin Infect Dis 2004; 39: 1241-1244.
16. Lass-Florl C, Kofler G, Kropshofer G, et al. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother 1998; 42: 497-502.
17. Holding KJ, Dworkin MS, Wan PC, et al. Aspergillosis among people infected with human immunodeficiency virus: incidence and survival. Clin Infect Dis 2000; 31: 1253-1257.